Compile Data Set for Download or QSAR
Report error Found 504 of affinity data for UniProtKB/TrEMBL: Q9NXS2
TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687847(US20240246981, Example 75)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687848(US20240246981, Example 76)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687846(US20240246981, Example 74)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652300(US20240059675, Example 4)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652305(US20240059675, Example 8)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687808(US20240246981, Example 36)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687805(US20240246981, Example 33)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687806(US20240246981, Example 34)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687812(US20240246981, Example 40)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687844(US20240246981, Example 72)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687778(US20240246981, Example 6)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652363(US20240059675, Example 32)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652318(US20240059675, Example 21)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687830(US20240246981, Example 58)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687835(US20240246981, Example 63)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM661126(US20240101544, Example 11 | 2-[4-(4-methyl-4H-1,2,...)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652324(US20240059675, Example 26)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687802(US20240246981, Example 30)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687834(US20240246981, Example 62)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687791(US20240246981, Example 19)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687855(US20240246981, Example 83)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM762870(US20250250252, Example 1)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652310(US20240059675, Example 13)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687853(US20240246981, Example 81)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687822(US20240246981, Example 50)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687827(US20240246981, Example 55)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687828(US20240246981, Example 56)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687825(US20240246981, Example 53)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652312(US20240059675, Example 15)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687794(US20240246981, Example 22)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687858(US20240246981, Example 86)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652313(US20240059675, Example 16)
Affinity DataIC50: 1nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652301(US20240059675, Example 5)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652303(US20240059675, Example 6)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687813(US20240246981, Example 41)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652299(US20240059675, Example 3)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687819(US20240246981, Example 47)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM762874(US20250250252, Example 5)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652304(US20240059675, Example 7)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687818(US20240246981, Example 46)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687807(US20240246981, Example 35)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652297(US20240059675, Example 1)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652298(US20240059675, Example 2 | US20240101544, Example ...)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM687831(US20240246981, Example 59)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/7/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM637820(US11834440, Compound 17B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM637822(US11834440, Compound 18B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM637816(US11834440, Compound 15B)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM652316(US20240059675, Example 19)
Affinity DataIC50: 2nMAssay Description:QPCT or QPCTL dependent conversion of N-terminal glutamine to pyroglutamate of CD47 was monitored via MALDI-TOF MS. Test compounds were dissolved in ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM637817(US11834440, Compound 16CR)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

TargetGlutaminyl-peptide cyclotransferase-like protein(Human)
Boehringer Ingelheim International

US Patent
LigandPNGBDBM637827(US11834440, Compound 25CR)
Affinity DataIC50: 2nMAssay Description:Preparation of working solution: 2×Glutaminyl Cyclase substrate was diluted in assay buffer to 5 M. 2×enzyme solution and QPCTL was diluted in assay ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/23/2024
Entry Details
US Patent

Displayed 1 to 50 (of 504 total ) | Next | Last >>
Jump to: